FP7Реинтеграция2010–2013

GS2DS · Systematic Analysis of Gene Synergies to Discover Drug Synergies

7РП — „Хора“ (Действия „Мария Кюри“)

Период
2010-09-01 → 2013-08-31
Финансиране от ЕС
75 000 €
Участници
1
Схема
MC-IRG

Линиите свързват координатора с партньорите.

Накратко на български

Взаимодействието между лекарствата се анализира чрез проучване на генетични връзки, например при combination на противогъбични средства. Това помага да се разбере как се постига терапевтичен ефект с по-ниски дози от отделните препарати.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Systematic Analysis of Gene Synergies to Discover Drug Synergies

Drug synergy allows a therapeutic effect to be achieved with lower doses of component drugs. Drug synergy can result when drugs target the products of genes that act in parallel pathways (‘specific synergy’). Such cases of drug synergy should tend to correspond to synergistic genetic interaction between the corresponding target genes. Alternatively, ‘promiscuous synergy’ can arise when one drug non-specifically increases the effects of many other drugs, for example, by increased bioavailability. In the research project funded by FP7 Marie Curie IRG Grant (268440), to assess the relative abundance of these drug synergy types, we examined 200 pairs of antifungal drugs in S. cerevisiae. We found 38 antifungal synergies, 37 of which were novel. While 14 cases of drug synergy corresponded to genetic interaction, 92% of the synergies we discovered involved only six frequently synergistic drugs. Although promiscuity of four drugs can be explained under the bioavailability model, the promiscuity of Tacrolimus and Pentamidine was completely unexpected. While many drug synergies correspond to genetic interactions, the majority of drug synergies appear to result from non-specific promiscuous synergy. These results and interpretations were published as an article in Molecular Systems Biology November 2011 and they represent Work Packages 1a, 1b, 2a, 3a and 3b in the proposed research plan. In the least period of the project, we optimized the correspondence between genetic interactions and a probabilistic drug target set to predict synergistic drug pairs (Work Package 2b. As part of work package 3b, in an effort to predict drug synergies, we assembled physicochemical descriptors of drugs and computationally analyzed their relationship with drug synergy. Finally, we systematically identified 93 suppressive drug interactions in yeast and analyzed possible mechanistic explanations for these interactions. These observations further our understanding of drug interactions. The major socio-economic aspect of this project is finding methods to predict synergistic drug pairs. In the course of the research activity, real synergistic drug pairs are found. These methods and examples may have a large impact on the understanding and controlling drug interactions, which can have positive or negative effects on human health.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Using multitherapeutics against disease is a promising direction in medicine. A particularly useful drug combination is a synergistic drug pair, where two drugs administered together produce a collective effect better than the added independent effects of both. Since drug interaction screening is an expensive experiment, most synergistic drug pairs are found by serendipity. In this proposal, we describe a research plan which aims to develop predictive tools for drug synergy. During the proposed research, drug pairs with synergistic antifungal activity will be discovered. A preliminary study has shown that these predictive tools are likely to succeed. The results of the proposed research will lead to a better understanding of drug interactions and their potential in medicine.

Оригинален текст от CORDIS (на английски).

Участници

  • SABANCI UNIVERSITESI · IstanbulКоординаторТурция

Връзки

Данни: CORDIS, © Европейски съюз